Share on StockTwits

SciClone Pharmaceuticals (NASDAQ:SCLN) CFO Lan Xie sold 36,468 shares of SciClone Pharmaceuticals stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $6.97, for a total value of $254,181.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

SciClone Pharmaceuticals (NASDAQ:SCLN) traded up 4.78% on Thursday, hitting $7.23. The stock had a trading volume of 798,340 shares. SciClone Pharmaceuticals has a 52-week low of $4.24 and a 52-week high of $7.12. The stock has a 50-day moving average of $5.63 and a 200-day moving average of $5.04. The company has a market cap of $369.3 million and a P/E ratio of 16.43.

SciClone Pharmaceuticals (NASDAQ:SCLN) last announced its earnings results on Monday, August 11th. The company reported $0.20 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.10 by $0.10. The company had revenue of $32.50 million for the quarter, compared to the consensus estimate of $33.40 million. During the same quarter in the prior year, the company posted ($0.04) earnings per share. The company’s quarterly revenue was up 10.9% on a year-over-year basis. Analysts expect that SciClone Pharmaceuticals will post $0.49 EPS for the current fiscal year.

Separately, analysts at Aegis reiterated a “buy” rating on shares of SciClone Pharmaceuticals in a research note on Friday, August 29th.

SciClone Pharmaceuticals, Inc (NASDAQ:SCLN) is a specialty pharmaceutical company.

Receive News & Ratings for SciClone Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciClone Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.